- Àrees i grups d'investigació
- Investigació Clínica
- Comités ètics
- Memòries científiques
- Projectes finançats
- Ajudes a la R+D+i
- Internacionalització
EUTOXRISK21. An Integrated EUropean ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century.
- Call
- H2020-PHC-33-2015-single-stage_RTD.
- Investigador principal
- Dr. José Vicente Castell Ripoll
- Role
- Participant
- Year
- 2015
The project will focus on repeated dose systemic toxicity (liver, kidney, lung and nervous system) as well as developmental/reproduction toxicity. EUToxRisk21 extensively integrates the adverse outcome pathway (AOP)-based toxicity testing concept, with advanced technologies, including high throughput transcriptomics, RNA interference, and high throughput microscopy, providing quantitative and mechanistic underpinning of AOPs and key events (KE). The project combines in silico tools and in vitro assays by computational modelling approaches to provide quantitative data on the activation of KE of AOP. This information, together with detailed toxicokinetics data, and in vitro-in vivo extrapolation algorithms forms the basis for improved hazard and risk assessment.